Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

AbbVie

Status: Withdrawn

Conditions: Rheumatoid Arthritis (RA)

Study type: Observational

Funder types: Industry

Identifiers

NCT02786563

P15-074

Details and patient eligibility

About

Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring system, and validate the applicability of different simplified US joint scoring systems.

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate to severe RA despite treatment with methotrexate (MTX).
• Eligible to use adalimumab according to the local label without any contraindication.
• Naïve to adalimumab, and participants with prior exposure to any other biologic disease-modifying antirheumatic drugs (DMARDs) should have experienced at least five half-lives of the biologics after treatment discontinuation.
• Participants for whom investigators decided to prescribe adalimumab as per local label and are initiating adalimumab at baseline.

Exclusion criteria

• Other inflammatory condition which may affect the signs on joints ultrasound (eg, gouty arthritis, or other chronic rheumatic disease besides RA).
• Currently being treated with or has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days of the baseline visit.
• Participants with contraindication or are not appropriate to use adalimumab according to local label or investigators' judgment.

Trial design

0 participants in 1 patient group

Participants with RA receiving adalimumab

Description:

This group contains participants in China with RA receiving adalimumab